Upstream Bio (UPB) Projected to Post Earnings on Thursday

Upstream Bio (NASDAQ:UPB) will likely be announcing its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter.

Upstream Bio Stock Down 3.0 %

UPB opened at $7.98 on Friday. The firm’s 50-day moving average is $12.60. Upstream Bio has a 52 week low of $6.65 and a 52 week high of $29.46.

Wall Street Analyst Weigh In

Several research analysts have commented on UPB shares. William Blair started coverage on shares of Upstream Bio in a report on Tuesday, November 5th. They set an “outperform” rating for the company. JPMorgan Chase & Co. initiated coverage on shares of Upstream Bio in a research report on Tuesday, November 5th. They set an “overweight” rating and a $38.00 target price on the stock. Piper Sandler initiated coverage on shares of Upstream Bio in a research report on Tuesday, November 5th. They set an “overweight” rating and a $75.00 target price on the stock. Finally, TD Cowen initiated coverage on shares of Upstream Bio in a research report on Tuesday, November 5th. They set a “buy” rating on the stock.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.